- View the Meeting Summary
The incidence of type 2 diabetes and its costs to the healthcare system are continuing to rise. Despite the availability of at least five drug classes for the treatment of type 2 diabetes, metformin remains the most widely used first-line pharmacotherapy. As medicine enters the genomic era, there is the opportunity to understand the genetics underlying inter-individual variation in pharmacological responses of metformin to achieve safer, more effective treatment in those who respond, deploy alternative therapies in those who do not, and develop new comparable agents. The goals of this workshop are to review the state of the science on metformin pharmacogenomics, discuss the scientific and clinical hurdles to furthering our knowledge of the variations in patient responses to metformin, and consider how to utilize effectively this increased understanding to improve patient outcomes in both the academic and private sectors. The workshop also will explore how the potential effectiveness of metformin for additional indications such as diabetes and cancer prevention, polycystic ovarian disease, and Alzheimer's disease can both aid and be aided by the understanding of metformin pharmacogenomics.
Jose Florez, Kathleen Giacomini, Alan Shuldiner
Aaron Pawlyk, Catherine McKeon, Myrlene Staten, Arthur Castle
The Mayflower Renaissance Washington, DC Hotel
1127 Connecticut Avenue N.W.
Washington, D.C. 20036
T: +1-(202) 347-3000
Aaron Pawlyk, Ph.D.
John Hare, M.S., CMP
The Scientific Consulting Group, Inc.